Virtu Financial’s Vaxcyte PCVX Stock Holding History

Virtu Financial’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-4,429	Closed	-$257K	–	2087
2026 Q1	$257K	Buy	+4,429	New	+$240K	0.01%	897
2024 Q4	–	Sell	-3,110	Closed	-$355K	–	1922
2024 Q3	$355K	Buy	+3,110	New	+$280K	0.02%	563

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Virtu Financial's PCVX Position: Q2 2026 in Review

Virtu Financial sold out of Vaxcyte (PCVX) in Q2 2026, closing a stake of 4,429 shares — an estimated $257K sold.

Virtu Financial first reported a position in PCVX in Q3 2024 and held it in 2 quarters. The position peaked at $355K in Q3 2024. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

Virtu Financial reported no remaining Vaxcyte position as of Q2 2026 after selling out during the quarter.
Virtu Financial sold 4,429 Vaxcyte shares in Q2 2026, an estimated $257K.
Virtu Financial first reported a position in Vaxcyte in Q3 2024 and held it in 2 quarters.
Virtu Financial's Vaxcyte position peaked at $355K in Q3 2024.
331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Virtu Financial's 13F filing for Q2 2026, filed 13 Aug 2026.